Considerations for the development of a prophylactic vaccine for Acinetobacter baumannii

Vaccine

Volumn 32, Issue 22, 2014, Pages 2534-2536

  Pachón, Jerónimo ^a   McConnell, Michael J ^a  

^a CSIC   (Spain)

Author keywords

Acinetobacter baumannii; Antibiotic resistance; Vaccine

Indexed keywords

ACINETOBACTER BAUMANNII VACCINE; BACTERIAL VACCINE; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; DRUG DESIGN; HUMAN; NONHUMAN; NOTE; PRIORITY JOURNAL; PROPHYLAXIS; VACCINATION;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; VACCINE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; BACTERIAL VACCINES; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; PNEUMONIA, VENTILATOR-ASSOCIATED;

EID: 84898545486     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.10.064     Document Type: Note

References (11)

1. Cooper M.A., Shlaes D. Fix the antibiotics pipeline. Nature 2011, 472(April (7341)):32.
2. McConnell M.J., Actis L., Pachón J. Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. FEMS Microbiol Rev 2013, (March (2)):130-155.
3. Bentancor L.V., O'Malley J.M., Bozkurt-Guzel C., Pier G.B., Maira-Litran T. Poly-N-acetyl-beta-(1-6)-glucosamine is a target for protective immunity against Acinetobacter baumannii infections. Infect Immun 2012, 80(February (2)):651-656.
4. Bentancor L.V., Routray A., Bozkurt-Guzel C., Camacho-Peiro A., Pier G.B., Maira-Litran T. Evaluation of the trimeric autotransporter Ata as a vaccine candidate against Acinetobacter baumannii infections. Infect Immun 2012, 80(October (10)):3381-3388.
5. McConnell M.J., Domínguez-Herrera J., Smani Y., López-Rojas R., Docobo-Pérez F., Pachón J. Vaccination with outer membrane complexes elicits rapid protective immunity to multidrug-resistant Acinetobacter baumannii. Infect Immun 2011, 79(January (1)):518-526.
6. McConnell M.J., Pachón J. Active and passive immunization against Acinetobacter baumannii using an inactivated whole cell vaccine. Vaccine 2010, 29(December (1)):1-5.
7. McConnell M.J., Rumbo C., Bou G., Pachón J. Outer membrane vesicles as an acellular vaccine against Acinetobacter baumannii. Vaccine 2011, 29(August (34)):5705-5710.
8. Harris G., Kuo Lee R., Lam C.K., Kanzaki G., Patel G.B., Xu H.H., et al. A mouse model of Acinetobacter baumannii-associated pneumonia using a clinically isolated hypervirulent strain. Antimicrob Agents Chemother 2013, 57(August (8)):3601-3613.
9. Fattahian Y., Rasooli I., Mousavi Gargari S.L., Rahbar M.R., Darvish Alipour Astaneh S., Amani J. Protection against Acinetobacter baumannii infection via its functional deprivation of biofilm associated protein (Bap). Microb Pathog 2011, 51(December (6)):402-406.
10. Luo G., Lin L., Ibrahim A.S., Baquir B., Pantapalangkoor P., Bonomo R.A., et al. Active and passive immunization protects against lethal, extreme drug resistant-Acinetobacter baumannii infection. PLoS One 2012, 7(1):e29446.
11. Russo T.A., Beanan J.M., Olson R., MacDonald U., Cox A.D., St Michael F., et al. The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization. Infect Immun 2013, 81(March (3)):915-922.